摘要
目的:探讨过氧化物酶体增殖激活物受体β(PPARβ)的表达及其与上皮性卵巢癌临床病理特征间的关系。方法:用免疫组织化学染色和半定量RT-PCR法检测PPARβ在正常卵巢组织和卵巢癌组织的表达。结果:PPARβ在上皮性卵巢癌和非癌组织均有表达,PPARβ的表达定位于细胞质中,在正常卵巢、卵巢交界性肿瘤、浆液性囊腺癌中PPARβ表达阳性率分别为20%、50%及89·1%。在浆液性囊腺癌中表达明显高于交界性肿瘤和正常卵巢组织(P<0·05),且与临床分期、组织学分级和淋巴结转移有关(P<0·05)。结论:PPARβ表达水平增高可能与卵巢上皮癌的分化转移有关。
AIM： To explore the possible relationship between expression of PPAR （pevoxisome prodiferator adivated receptor） β and clinical pathological features of epithelial ovarian carcinoma （EOC）. METHODS： PPARI5 expressions in normal ovaries （n= 10）, ovarian bordline tumors （n = 10）, and ovarian serous cystadenocarcinomas （n = 46） were investigated by immunohistochemistry and RT-PCR. RESULTS; PPARI5 protein was expressed in normal ovaries and ovarian cancer. PPARI5 protein was found in cytoplasm of tumor cell. PPARI5 expression was 20% revealed in normal ovaries, 50% in bordline tumors 89.1% in serous cystadenocarcinomas（ P 〈 0.05 ）, significantly higher than that in bordline tumors （ P 〈 0.05）. PPARβ expression was positively correlated with tumor stage, histological grade and lymphonode metastasis （ P 〈 0.05 ）. CONCLUSION： High expression of PPARβ may be related with the differentiation and metastasis of epithelial ovarian carcinoma.
出处
《细胞与分子免疫学杂志》
CAS
CSCD
北大核心
2007年第7期630-632,共3页
Chinese Journal of Cellular and Molecular Immunology
